fda compounding semaglutide crackdown october 2025 restricts non-approved compounded GLP-1 weight loss products Important Update: Changes to Compounded

Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review

First, the Company has resubmitted to the FDA its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults

Immune regulation in T1D and T2D: prospective role of foxp3+ Treg cells in disease pathogenesis and treatment

Impact of insulin and insulin resistance on brain dopamine signalling and reward processingan underexplored mechanism in the pathophysiology of depression

What should I do if I run out of injection supplies

Let diners control every topping, every sauce drizzle, every cheese sprinkle